BioEVEN

BioEven is a clinical-stage biopharmaceutical company based in South Korea, specializing in the development of novel small molecule therapeutics for inflammatory and autoimmune diseases. The company's lead candidate, BE-101, is a selective Janus kinase 1 (JAK1) inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of atopic dermatitis. BioEven's pipeline also includes programs targeting psoriasis and alopecia areata, leveraging its expertise in medicinal chemistry to create highly selective and potent kinase inhibitors. The company aims to provide safer and more effective oral treatment options for patients suffering from chronic skin conditions by improving upon the safety profiles of first-generation pan-JAK inhibitors.